Methods of treating colon cancer utilizing tumor-specific antibodies
AssigneeLudwig Institute for Cancer Research
InventorsSydney Welt, Gerd Ritter, Leonard Cohen, Clarence Williams, Jr., Elizabeth Carswell Richards, Mary John, Lloyd J. Old
Life of this patent
Estimating the term…
Abstract
This invention relates to methods of reducing the effects of colon cancer tumors. Various agents are conjugated to monoclonal antibodies which are specific for colon cancer cells. The conjugates are administered to patients having colon cancer such that the effects of the cancer are reduced.
Claims11
A method for promoting tumor regression or reducing serum CEA levels in a subject comprising administering to said subject a pharmaceutically effective amount of a conjugate of an antibody selected from the group consisting of monoclonal antibody A33 produced by hybridoma cell line ATCC HB 8779, 100-210 produced by hybridoma cell line ATCC HB 11764 and 100-310 produced by hybridoma cell line ATCC HB 11028 and a radioisotope selected from the group consisting of .sup.125 I, .sup.131 I, .sup.99 Tc, .sup.90 Y and .sup.111 In.
A method for promoting tumor regression or reducing serum CEA levels in a subject comprising administering to said subject a pharmaceutically effective amount of a conjugate of a murine, humanized, chimeric, trimeric, heteromeric or single chain form of an antibody selected from the group consisting of monoclonal antibody A33 produced by hybridoma cell line ATCC HB 8779, 100-210 produced by hybridoma cell line ATCC HB 11764 and 100-310 produced by hybridoma cell line ATCC HB 11028 and a radioisotope selected from the group consisting of .sup.125 I, .sup.131 I, .sup.99 Tc, .sup.90 Y and .sup.111 In.
Dependencies are inferred from the claim text.